MedTrace Logo

Effect of Budesonide on Exhaled Nitric Oxide in Asthmatic Children

NCT00522782 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2009-01-23

No results posted yet for this study

Summary

To study the improvement in airway inflammation in children with asthma non-invasively with exhaled breath NO, a marker of inflammation, after therapy with nebulized budesonide as 0.5mg daily.

Conditions

Interventions

DRUG

Nebulized Budesonide

Pulmicort Respules 0.5mg/2cc

DEVICE

Nitric Oxide Analyzer

Niox NO analyzer

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • AAADRS Clinical Research Center

    lead OTHER

Principal Investigators

  • Miguel J Lanz, MD · Principal Investigator

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Max Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2008-12-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00522782 on ClinicalTrials.gov